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Objective: Large cell neuroendocrine carcinoma of the lung is a newly recognized
clinicopathologic entity. The clinical characteristics and optimal treatment of pa-
tients with large cell carcinomas are not yet established. The aim of this study was
to define the clinicopathologic characteristics of large cell neuroendocrine carci-
noma.
Methods: The histologic characteristics of the patients receiving an initial diagnosis
of poorly differentiated non–small cell lung carcinoma (n  484), small cell
carcinoma (n  55), carcinoid (n  31), and large cell neuroendocrine carcinoma
(n  12) were retrospectively reviewed according to World Health Organization
criteria. Immunohistochemistry was performed to confirm the neuroendocrine phe-
notype. The outcomes and other clinical characteristics of those patients with large
cell neuroendocrine carcinoma were retrospectively analyzed and compared with
those of patients with poorly differentiated carcinoma of other histologic types.
Results: A total of 87 patients were given a diagnosis of large cell neuroendocrine
carcinoma after the histologic review. These patients comprised 3.1% of all patients
undergoing resection for primary lung cancer during the same period. The overall
5-year survival was 57%. The 5-year survivals of patients with stage I, II, III, and
IV disease were 67%, 75%, 45%, and 0%, respectively. There was no statistically
significant difference between the overall survival of patients with large cell neu-
roendocrine carcinoma and those with other non–small cell lung cancers. There was
a significant difference between the survival of patients with stage I large cell
neuroendocrine carcinoma and that of patients with the same stage of other non–
small cell lung carcinomas. The site of the first documented recurrence was
locoregional in 12 patients (34%), distant metastases in 20 patients (57%), and both
simultaneously in 3 patients. Locoregional lymph node recurrences were observed
frequently. More than 80% of recurrences were found within 1 year after the
operation.
Conclusion: In terms of prognosis, large cell neuroendocrine carcinoma is distinctly
different from other non–small cell lung cancers. The prognosis of large cell
neuroendocrine carcinoma was poor, even for early stage disease; the prognosis of
the stage I disease of large cell neuroendocrine carcinoma was poorer than that of
the same stage of other non–small cell lung cancers. Because of its aggressive
clinical behavior and poor prognosis, large cell neuroendocrine carcinoma should be
recognized as one of the poorest prognostic subgroups among primary lung cancers,
and therefore novel therapeutic approaches should be established.
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Neuroendocrine tumors of the lung repre-sent a wide spectrum of pathologic enti-ties. On the basis of histologic character-istics and clinical behavior, at one end ofthe spectrum are typical carcinoid tumors,with a low incidence of metastases and
excellent prognosis after surgical resection. At the other end
of the spectrum are small cell carcinomas (SCLCs) that
metastasize early. Between these extremes, there is atypical
carcinoid, as proposed by Arrigoni and colleagues1 in 1972.
Travis and coworkers2 attempted to define tumors with wide
histologic similarity with oat cell carcinoma consisting of
large cells and proposed large cell neuroendocrine carci-
noma (LCNEC) as the fourth category among neuroendo-
crine tumors of the lung.3-7 The histologic criteria of LC-
NEC proposed by the World Health Organization (WHO) in
1999 were as follows8: (1) a tumor with a neuroendocrine
morphologic features (organoid nesting, palisading, ro-
settes, and trabeculae); (2) high mitotic rate of 11 or greater
per 2 mm2; (3) necrosis (often large zones); and (4) cyto-
logic features of a non–small cell carcinoma (NSCLC; ie,
large cell size, low nuclear/cytoplasmic ratio, vesicular or
fine chromatin, and/or frequent nucleoli). Although a few
studies have described the clinicopathologic features of
LCNEC,9-11 these studies contain a rather small number of
cases. The present study is based on the largest series of
LCNEC cases from a single institute. The aim of this study
was to delineate the clinical characteristics and prognosis of
patients with LCNEC.
Methods
Patients
Of 2790 patients who underwent surgical resection for primary
lung cancer during the 18-year period between 1982 and 1999 at
the National Cancer Center Hospital, Tokyo, 572 patients with the
following histologic diagnoses were reviewed to extract cases of
LCNEC: poorly differentiated adenocarcinoma (n  216); poorly
differentiated squamous cell carcinoma (n  141); large cell
carcinoma (LCC, n 117); SCLC (n 55); carcinoid tumor (n
31); and LCNEC (n  12). During this period, atypical carcinoid
was not identified in our pathology files.
Pathology Review
According to the histologic criteria described in the WHO classi-
fication,8 representative routine hematoxylin and eosin–stained
sections of these 572 patients were independently reviewed by 3
investigators (H.T., Y.M., and A.M.), and discrepancies were
resolved by means of joint view of the slides under a multiheaded
microscope. A representative photomicrograph of LCNEC is
shown in Figure 1. Immunohistochemistry was performed to con-
firm the neuroendocrine phenotype. One of the representative
formalin-fixed, paraffin-embedded tissue blocks of each case was
selected for immunostaining. The sections were autoclaved for 10
minutes in 10 mmol/L citrate buffer (pH, 6.0) for antigen retrieval
before incubation with the primary antibody. Primary antibodies
against 3 neuroendocrine markers, neural cell adhesion molecule
(NCC-Lu-243, Nippon Kayaku Co, Ltd, Tokyo, Japan), chromo-
granin A (DAKO Corporation, N.S., Glostrup, Denmark), and
synaptophysin (DAKO), were used. Immunoreaction was detected
by using a labeled streptavidin-biotin method and was visualized
with 3,3-diaminobenzidine, followed by counterstaining with he-
matoxylin. The degree of immunostaining of the neuroendocrine
markers was scored as negative, focal (10% of tumor cells
stained; Figure 2, A), patchy (10%-50% stained; Figure 2, B), and
diffuse (50% stained; Figure 2, C). A tumor that stained focally
for at least one of the 3 neuroendocrine markers was judged
positive for neuroendocrine phenotype. A revised diagnosis of
LCNEC was made when the neuroendocrine phenotype was con-
firmed and when all 3 investigators agreed with the diagnosis.
Clinical Findings and Statistical Analysis
Clinical information was extracted from medical records. The
stage of disease was based on the TNM classification using the
International Union Against Cancer (UICC) staging system.12 The
overall survival of the patients was calculated by means of the
Kaplan-Meier methods.13 Comparison of survival curves of dif-
ferent categories between patients with LCNEC and patients di-
agnosed as having disease of other histologic types was performed
by log-rank tests.
Results
Pathology Review
Eighty-eight of 572 patients who underwent pathology re-
view had histologic morphologic characteristics of LCNEC.
Because 1 of the patients had negative results for all 3
neuroendocrine markers, the case was excluded from the
LCNEC category and was categorized as LCC in further
analysis. The remaining 87 patients had positive results for
at least 1 of 3 neuroendocrine markers. Each of the 3
neuroendocrine markers was expressed in more than 80% of
LCNEC cases (Table 1). Fifty-nine (68%) of the patients
had positive results for all 3 neuroendocrine markers (Table
2). Less than half of the cases stained diffusely in each
immunohistochemical section. Eighty-seven patients with
LCNEC comprised 3.1% of all the patients who underwent
surgical resection for primary lung cancer during the same
period. The results of histologic review are shown in Table
3. Twenty-four (44%) of 55 patients with SCLCs were
converted to LCNEC. Five patients with LCNEC were
combined with other histologic types of NSCLC (squamous
cell carcinoma in 2, adenocarcinoma in 1, both squamous
cell carcinoma and adenocarcinoma in 1, and LCC in 1).
Clinical Profiles
Of the 87 patients with LCNEC identified, 77 were men and
10 were women. Mean age was 68 years (range, 37-82
years). Eighty-five (98%) patients had a history of habitual
cigarette smoking. The level of serum carcinoembryonic
antigen was increased in 42 (49%) of 86 patients. An
elevation of the level of serum neuron-specific enolase and
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pro-gastrin–releasing peptide was found in 8 (19%) of 48
patients and in 1 (11%) of 9 patients, respectively. No
evidence of paraneoplastic syndrome was found in any of
the 87 patients at the presentation. The postoperative stage
distribution of 87 patients, according to the UICC staging
system, was as follows: IA, 20; IB, 21; IIA, 3; IIB, 10; IIIA,
17; IIIB, 13; and IV, 3. The operative mode performed was
as follows: pneumonectomy, 12 patients; bilobectomy, 6
patients; lobectomy, 61 patients; and limited resection, 8
patients. A complete mediastinal lymph node dissection was
performed in 60 (69%) patients, and mediastinal lymph
node metastasis was found in 17 (28%) of these patients.
Preoperative chemotherapy was administered for 5 pa-
tients, and a substantial response was observed in 1 patient.
A total of 12 patients had postoperative chemotherapy.
Because of the original histologic diagnosis of SCLC, 11
patients received postoperative chemotherapy with a cispla-
tin-based regimen. Tumor recurrences were observed in 5
(46%) patients of this group.
Prognosis
Thirty-one patients died of LCNEC, and 4 patients were
alive with LCNEC. The survival of patients with LCNEC,
other poorly differentiated NSCLC (n  426), LCC (n 
102), and SCLC (n  31) was compared for all stages
(Figure 3). The overall 5-year survival of 87 patients with
LCNEC was 57%. The 5-year survivals of patients with
stage I, II, III, and IV disease were 67%, 75%, 45%, and
0%, respectively. No significant difference was found in
survival between patients with LCNEC and those with other
poorly differentiated NSCLC (P  .91), between patients
with LCNEC and LCC (P .13), and between patients with
LCNEC and SCLC (P  .59). The survival was further
analyzed for patients with stage I disease. The 5-year sur-
vivals of patients with stage I LCNEC, poorly differentiated
NSCLC, and LCC were 67%, 88%, and 92%, respectively.
There were significant difference in survival between the
patients with LCNEC and those with poorly differentiated
NSCLC (P  .003, Figure 4) and between patients with
LCNEC and those with LCC (P  .03, Figure 5). However,
there was no significant difference in survival between
patients with stage I LCNEC and those with SCLC (P 
.87, Figure 6). There was no correlation between the pattern
of staining of neuroendocrine markers and survival.
Of the 87 patients with LCNEC, 35 patients experienced
tumor recurrence. The sites of first-documented recurrence
are shown in Table 4. Locoregional recurrence was ob-
Figure 1. A, Representative photomicrograph of LCNEC. Organoid pattern, palisading, and necrosis are shown.
(Hematoxylin and eosin; original magnification 100.) B, Tumor cells are large and polygonal with abundant and
finely granular cytoplasm, easily discernible nucleoli in some cells. Note also rosette-like structures. (Hematoxylin
and eosin; original magnification 400.)
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served in 44% of patients. The mediastinal and supraclavic-
ular lymph nodes were a common site for locoregional
recurrence. A majority of tumor recurrence was seen early
after the operation: 82% within a year and 91% within 2
years (Table 5). Of 35 patients, 18 received radiotherapy for
recurrence in a palliative setting. Complete response was
radiologically observed in 5 patients.
Discussion
LCNEC of the lung was initially characterized by Travis
and colleagues,2 forming a separate category of neuroendo-
crine tumors of the lung. Many different classification sche-
mas of pulmonary neuroendocrine tumors have been pro-
posed.3-9,14 In 1999, the WHO proposed a new classification
of pulmonary neuroendocrine tumors.8 The criteria for di-
Figure 2. Representative staining of chromogranin A in LCNEC cases: A, Focal; B, patchy; C, diffuse. (Immunostain;
original magnification 400.)
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agnosis of LCNEC were authorized in this classification.
However, the clinical behaviors of LCNEC remain un-
known. The present study is the first to analyze a large
number of patients with LCNEC according to the WHO
classification. The patients with LCNEC in our series com-
prised 3.1% of all the patients undergoing surgical resection
for primary lung cancer during the same period. The present
findings agree with those of Jiang and associates,9 who
reported that 2.8% of all the resected primary lung cancers
were LCNECs in their series of patients. Thus, the actual
incidence of LCNEC among resectable primary lung cancer
appears to be around 3%.
In the diagnosis of LCNEC, a discordance between his-
tologic findings and immunohistochemical results may oc-
casionally occur. Tumors showing neuroendocrine morpho-
logic features but lacking the positive neuroendocrine
phenotype can be called LCCs with neuroendocrine mor-
phologic features.8 Whether such tumors behave as LCNEC
or as LCC of nonneuroendocrine type remains controver-
sial. In the present study there was only 1 patient with LCC
with neuroendocrine morphologic features, probably be-
cause of the strict application of histologic criteria, the
sensitive and reliable immunohistochemical technique for
the 3 markers used, and the careful microscopic examina-
tion of its result. For chromogranin A staining, for example,
a single but definitively positive tumor cell was counted as
positive. This successful exclusion of LCC with neuroen-
docrine morphologic characteristics has made clinicopath-
ologic analysis of LCNEC in this study understandable and
reliable. However, the number of positive cells and their
distribution was variable among patients, as shown in Table
1. Therefore, for the purpose of reliable preoperative patho-
logic diagnosis, it is worth exploring novel neuroendocrine
markers that would label most of the tumor cells in the
biopsy or cytology specimen.
Several unique clinical features of LCNEC were clearly
demonstrated in the present study.2-9 Among them, male
predominance of the affected patients and apparent associ-
ation with habitual tobacco smoking may suggest the pres-
ence of common causative factors to squamous cell carci-
noma, SCLC, and LCNEC. The prognosis of patients with
LCNEC was significantly poorer than that of patients with
other NSCLCs at stage I disease, which was almost com-
parable with that of patients with SCLC. Furthermore, the
disease-free interval of the patients with LCNEC was much
shorter. Thus, as demonstrated by a large number of cases in
this study, LCNEC should be recognized as a high-grade
malignancy. Obviously, it is important to separate LCNEC
distinctly not only from typical and atypical carcinoid tu-
mors but also from poorly differentiated NSCLC of other
histologic types. As for tumor markers, previous studies
showed that a serum level of pro-gastrin–releasing peptide
was elevated at 70% for SCLC and at 2% to 4% for
NSCLC.16-19 The elevation of serum neuron-specific eno-
lase level was also reported in 40% to 60% of patients with
SCLC and in 5% to 20% of patients with NSCLC.17,18,20,21
Although the elevation of a serum level for these 2 makers
was shown in the present study, it was not so frequent as
was reported in SCLC. In terms of tumor markers, the
pattern of elevation in serum level seemed to have some
resemblance to those of NSCLC rather than those of SCLC.
Interobserver differences in the diagnosis of LCNEC
TABLE 2. Neuroendocrine markers expressed per case
No. of NE markers
expressed per case No. of cases (%)
At least 1 marker 87 (100)
At least 2 markers 74 (85)
All 3 markers 59 (68)
NE, Neuroendocrine.
TABLE 1. Pattern of immunohistochemical staining for synaptophysin, neural cell adhesion molecule, and chromogranin
A
NE markers
Pattern of immunohistochemical staining
Negative Focal Patchy Diffuse Positive/eligible case (%)
Synaptophysin 8 25 14 38 77/85 (91)
NCAM 7 28 18 33 79/86 (91)
Chromogranin A 15 29 15 28 72/87 (82)
NE, Neuroendocrine; NCAM, neural cell adhesion molecule.
TABLE 3. Histologic review
Initial diagnosis
No. of
patients
No. of patients given new
diagnosis of LCNEC (%)
P/D AD 216 26 (12)
P/D SQ 141 10 (7)
LCC 117 15 (13)
SCLC 55 24 (44)
Carcinoid 31 0
LCNEC 12 12
Total 572 87 (15)
P/D AD, Poorly differentiated adenocarcinoma; P/D SQ, poorly differenti-
ated squamous cell carcinoma.
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should be investigated.23 In the course of establishment of
the WHO histologic criteria, Travis and colleagues23 studied
interobserver differences in the application of the proposed
criteria. In their study the observers were the members of
the WHO pathology committee who repeatedly examined
and discussed cases together and then described the criteria.
Even in that study they commented that separation between
LCNEC and SCLC appeared to be problematic. In the
present study, 44% (24 patients) of the previously diag-
nosed cases of SCLC were reclassified as LCNEC after the
Figure 3. Survival curves of patients with LCNEC (n  87), other poorly differentiated NSCLCs (n  426), LCC (n 
102), and SCLC (n  31) for all stages.
Figure 4. Survival curves of 41 patients with LCNEC of stage I and 126 patients with other poorly differentiated
NSCLCs of stage I (P  .003, log-rank test).
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review that required agreement by 3 investigators. As for
the 24 cases, most of which were initially diagnosed as
SCLC of intermediate cell type, the changes of histologic
diagnosis from SCLC to LCNEC were mainly based on the
cytologic findings, such as large cell size, coarse nuclear
chromatin, and frequent and prominent nucleoli. According
to the findings that LCNEC and SCLC are closely related
biologically and that their histopathologic distinction may
be difficult and also that survival after surgical resection is
almost equivalent, the need for the critical distinction be-
tween the 2 tumor categories should now be open to ques-
tion. It is worth considering that a diagnosis of high-grade
Figure 5. Survival curves of 41 patients with LCNEC of stage I and 29 patients of LCC of stage I (P  .03, log-rank
test).
Figure 6. Survival curves of 41 patients with LCNEC of stage I and 9 patients with SCLC of stage I (P .87, log-rank
test).
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neuroendocrine tumor of the lung, covering both tumor
categories, would be biologically correct and would provide
information necessary for making a clinical decision in
many situations. In the light of the clinicopathologic fea-
tures described here, it is also natural to claim that in a lung
tumor classification LCNEC is better classified as a subtype
of the neuroendocrine neoplasm family, which consists of
typical carcinoid tumors, atypical carcinoid tumors, and
SCLC and not as a subtype of LCC.
The optimal treatment of patients with LCNEC remains
to be established. Because their poor prognosis is compa-
rable with that of SCLC, it appears necessary to clarify that
combined modality treatment or other novel therapeutic
approaches would be effective.
In conclusion, LCNEC should be recognized as having a
poor prognosis. The survival of patients with stage I LC-
NEC was significantly poorer than that of patients with the
same stage of poorly differentiated NSCLC of other histo-
logic types. Because of the extremely poor prognosis and
aggressive nature of this tumor, novel therapeutic ap-
proaches need to be explored.
We thank Ms T. Shimizu for excellent technical assistance and
to Mr S. Osaka for photographs.
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TABLE 4. The site of first documented recurrence (n  35)
Site No. of cases (%)
Distant metastases 20 (56)
Brain 8
Liver 7
Bone 5
Lung 3
Locoregional recurrence 12 (35)
Mediastinal node 8
Supraclavicular node 4
Bronchial stump 3
Both sites simultaneously 3 (9)
TABLE 5. Time to recurrence (n  35)
Time to recurrence No. of cases (%)
1 6 mo 18 (50)
712 mo 11 (32)
1324 mo 3 (9)
24 mo 3 (9)
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